Drugs / ASM8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00264966 | Dec 2005 → Apr 2006 | asthma | Syntara | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01380236 | Nov 2011 → Jun 2012 | asthma | Syntara | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASM8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00264966 ↗ |
| Known as | TPI ASM8 | “The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the...” PMID 18244953 ↗ Jan 2008 |
| Action | Inhibit | “designed to inhibit allergic inflammation by down-regulating human CCR3” PMID 18244953 ↗ Jan 2008 |
| Modality | Antisense oligonucleotide | “two modified phosphorothioate antisense oligonucleotides” PMID 18244953 ↗ Jan 2008 |
| Route | Inhaled | “inhaled TPI ASM8” PMID 18244953 ↗ Jan 2008 |
| Target | CCR3 | “down-regulating human CCR3” PMID 18244953 ↗ Jan 2008 |